December 2023 - Page 7 of 8

Dr. Jiayu Wang: Revisiting International Conferences with Promising Efficacy Data – Domestic Innovative CDK4/6 Inhibitor Birociclib as a New Choice for HR+/HER2-MBC Treatment

By Mourabit Halima 2023.12.07

Editor's Note: During the 2023 European Society for Medical Oncology (ESMO) Annual Meeting, a Phase II multi-center clinical trial's results, led by Academician Xu Binghe and his team from the…

ESMO 2023 | SKB264 (TROP2-ADC) Shows Promise in the Treatment of HR+/HER2- Metastatic Breast Cancer, Advancing in Multiple Cancer Types

By Lisa Cui 2023.12.07

TROP2 (Trophoblast Cell-Surface Antigen 2) is highly expressed in various solid tumors, making it a hot target in the field of oncology. The development of antibody-drug conjugates (ADCs) targeting this…

2023 ESMO Congress Reveals YOUNGBC-21 Study Results

By Mourabit Halima 2023.12.07

Editor's note: HER2-positive metastatic breast cancer (HER2+ MBC) has seen the emergence of several new drugs, but the combination of Pyrotinib with dual targeting therapy remains the preferred first-line option.…

Dr. Tao Sun & Dr. Yehui Shi: Eribulin Combination Therapy Shines for Breast Cancer Patients, Providing More Treatment Options

By Mourabit Halima 2023.12.05

Editor's Note: Breast cancer has become the most common malignant tumor globally, with approximately 30% to 40% of early-stage breast cancer patients ultimately progressing to advanced breast cancer.At this year's…

Dr. Liang Han: Phase III MATTERHORN Study Shows Significant Improvement in pCR for Neoadjuvant Treatment of Gastric Cancer with Pembrolizumab

By Mourabit Halima 2023.12.05

Editor's Note:This 2023 ESMO Annual Meeting, in the field of gastric cancer, the global Phase III MATTERHORN study of the anti-PD-L1 antibody pembrolizumab in combination with the FLOT regimen for…

ESMO Exclusive Interview | Professor Huiyan Luo : Significant Efficacy of the Combination of Anti-PD-L1/TGF-βRII Dual-Target Antibody SHR-1701 with Bevacizumab in the Treatment of Advanced Solid Tumors

By Mourabit Halima 2023.12.04

Editor's Note: The 2023 European Society for Medical Oncology (ESMO) Annual Meeting took place from October 20th to 24th in Madrid, Spain. The Oncology Insights Reporting Team delved deep into…

ESMO 2023 | Professor Ning Liao: The Extension of the T-DXd Anti-HER2 Landscape in DESTINY-PanTumor01

By Lisa Cui 2023.12.04

Editor's Note: Anti-HER2 therapy has traditionally been implemented based on HER2 expression detected through immunohistochemistry. In clinical practice, a small subset of patients with HER2-negative expression may have HER2 gene…

ESMO China Voice | Professor Shichun Lu : Targeted Immunotherapy Offers Hope for Curative Resection and Long-Term Survival in Unresectable Liver Cancer

By Lisa Cui 2023.12.04

Due to the insidious nature of liver cancer, most patients are diagnosed in the advanced stages, losing the opportunity for curative surgery and facing a poor prognosis. In recent years,…

ESMO Big Shot Face to Face | Professor Shun Lu : Roxadustat Leads the Way in CIA Management

By Mourabit Halima 2023.12.04

The 2023 European Society for Medical Oncology (ESMO) Congress opened grandly in Madrid, Spain on October 20. Top global oncology experts gathered to discuss and share the latest international advances…

ESMO 2023: Prof. Feng Wang – “Combination Targeted Immunotherapy” Opens a New Era of Precision Treatment for Esophageal and Gastric Cancer in China

By Mourabit Halima 2023.12.04

Editor's note: The 2023 ESMO Annual Meeting took place in Madrid, Spain, from October 20th to 24th. As a prestigious annual event in the field of oncology, it unveils cutting-edge…